Shares of Neumora Therapeutics, Inc. (NMRA) are slipping over 15% on Monday morning after the phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA).
NMRA is currently trading at $11.40, down $2.16 or 15.89%, on the Nasdaq. The stock opened its trading at $11.07 after closing Friday's trading at $13.56. The stock has traded between $9.35 and $21.00 in the past 52-week period.
Neumora Therapeutics is a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs.
Neumora Therapeutics announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company's M4 PAM franchise. The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits.
Following this action, the Phase 1 single ascending dose / multiple ascending dose study with NMRA-266 has been paused. Approximately 30 participants have been dosed in the Phase 1 study, with no evidence of convulsions observed in any participant.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.